水蛭提取液对体外培养恒河猴视网膜血管内皮细胞生长的影响
|
摘要
目的
研究中药水蛭对体外培养视网膜血管内皮细胞的作用,探讨水蛭抗新生血管生成的作用及机制,为开辟新的抗新生血管生成药物提供依据,为中药新药研究和开发提供实验依据。
方法
1.体外培养恒河猴视网膜血管内皮细胞(RF/6A),免疫组化进行细胞鉴定:
2.选择终浓度为0mg/ml、8m/ml、16mg/ml、32mg/ml、64mg/ml、128mg/ml的水蛭提取液,分别作用于体外培养的RF/6A 24h后,观察细胞生长情况,以MTT法测定OD值,并计算出24h半数抑制浓度IC_(50),筛选最佳抑制作用的药物浓度;
3.选择终浓度为0u/ml、2.5u/ml、5u/ml、10u/ml、20u/ml的凝血酶,分别作用于体外培养的RF/6A 24h后,观察细胞生长情况,以MTT法测定OD值,筛选最佳诱导增殖的药物浓度:
4.应用流式细胞术,观察水蛭提取液对体外培养的RF/6A细胞周期的影响:
5.应用酶联免疫法,检测各药物组内细胞培养液中MMP-2的含量;
6.应用放射免疫法,检测各药物组内细胞培养液中Ⅳ-C的含量。
结果
1.RF/6A具有血管内皮细胞的特点,Ⅷ因子相关抗原表达阳性,可以用于眼部病变的研究:
2.体外培养的RF/6A指数增长期为48-72h;
3.高浓度水蛭提取液对体外培养的视网膜血管内皮细胞具有抑制增殖作用,低浓度有促进增殖的作用:24hIC_(50)为97mg/ml;选择64mg/ml水蛭提取液为本实验的最佳抑制浓度;
4.20u/ml的凝血酶对体外培养的视网膜血管内皮细胞具有促进增殖作用,选择此浓度用于后期的实验:
5.水蛭提取液将体外培养中视网膜血管内皮细胞的细胞周期抑制于G1期;凝血酶组细胞多处于S期;水蛭提取液抑制了凝血酶对视网膜血管内皮细胞的作用;
6.水蛭提取液可以降低体外培养视网膜血管内皮细胞的ECM中MMP-2的含量,并随时间的增加,其作用有减弱的趋势;凝血酶组随着时间的增加,其作用有增强的趋势;
7.水蛭提取液可以促进体外培养视网膜血管内皮细胞的ECM中Ⅳ-C的合成,并随作用时间的持续,合成有增加趋势;凝血酶组随着作用时间的增加,有轻度促Ⅳ-C的合成增加的趋势,但与正常组相比,有降低Ⅳ-C合成,促进ECM降解作用;2h时水蛭提取液有降低凝血酶促进ECM降解的作用。
结论
1.64mg/ml水蛭提取液对体外培养的视网膜血管内皮细胞具有抑制作用:
2.64mg/ml水蛭提取液可以改变体外培养的凝血酶诱导的视网膜血管内皮细胞的生长周期,对凝血酶诱导的细胞增殖有抑制作用:
3.64mg/ml水蛭提取液促进了体外培养中凝血酶诱导下细胞微环境中Ⅳ-C的合成、抑制了MMP-2的分泌,改变了细胞生长的微环境,对新生血管的形成有抑制作用。
OBJECTIVE
To study the action of leech on retinal vascular epithelium cell in vitro,probe the action and mechanism of leech on anti-Vascularization,and give the prove for exploitation and study on new anti-Vascularization medicine.
METHODS
1.Cultured RF/6A in vitro,and identified cell by immunohistochemical method;
2.Cultured RF/6A in vitro with different final concentration of Extract of leech (0mg/ml、8mg/ml、16mg/ml、32mg/ml、64mg/ml、128mg/ml),used Colorimetry MTT to detect viability of RF/6A at 24 hour,and calculated the 50%inhibitory concentration(IC_(50)) for choosing the right concentration of Exact of leech at 24 hour;
3.Cultured RF/6A in vitro with different final concentration of thrombin(0u/ml、2.5u/ml、5u/ml、10u/ml、20u/ml),and used Colorimetry MTT to detect viability of RF/6A at 24 hour for choosing the right concentration of thrombin;
4.Used flow cytometry to research the influence of Group Extract of leech、Group thrombin、Group mixing and the control on cell cycle of RF/6A cultured in vitro;
5.Used euzymelinked immunosorbent assay to study the influence of every group on MMP-2 of RF/6A cultured in vitro;
6.Used radio-immunity to study the influence of every group onⅣ-C of RF/6A cultured in vitro.
RESULTS
1.RF/6A had the feature of vascular epithelium cells,had positive antigen presentation of factorⅧ,could be usede to study the ophthalmic diseases;
2.Exponential phase of growth of RF/6A cultured in vitro was the 48-72 hour;
3.High concentration of Extract of leech had inhibition on proliferation of retinal vascular endothelial cell cultured in vitro,low concentration had enhancement on proliferation,the 50%inhibitory concentration(IC_(50)) at 24 hour was 97mg/ml,Extract of leech of concentration 64mg/ml was chosen to be the right concentration for this experiment;
4.Thrombin of concentration 20u/ml had enhancement on proliferation of retinal vascular endothelial cell cultured in vitro,and was chosen to be the right concentration for this experiment;
5.Most cells cultured in vitro were in the phrase G1 with Extract of leech,in the Group thrombin most were in the phrase S,Extract of leech had inhibition on the action of thrombin on generation cycle of retinal vascular endothelial cell cultured in vitro;
6.The level of MMP-2 was decreased in Group Extract of leech,and it was increased in Group thrombin in vitro;
7.The synthesis ofⅣ-C was increased in Group Extract of leech in vitro,and it was lightly increased in Group thrombin,while controlled with the normal,it was lower in Group thrombin,thrombin could enhance the degradation of ECM,which could be weekened by leech at 2h.
CONCLUSION
1.Extract of leech of concentration 64mg/ml has the inhibition on proliferation of retinal vascular endothelial cell cultured in vitro;
2.Extract of leech of concentration 64mg/ml can change the growth cycle of retinal vascular endothelial cell cultured in vitro and inhibit the cell proliferation induced by thrombin;
3.Extract of leech of concentration 64mg/ml can increase the synthesis ofⅣ-C, decrease the secretion of MMP-2 in the cell microenvironment cultured in vitro induced by thrombin,and change the microenvironment,maybe Extract of leech has the effect on anti-Vascularization.
研究中药水蛭对体外培养视网膜血管内皮细胞的作用,探讨水蛭抗新生血管生成的作用及机制,为开辟新的抗新生血管生成药物提供依据,为中药新药研究和开发提供实验依据。
方法
1.体外培养恒河猴视网膜血管内皮细胞(RF/6A),免疫组化进行细胞鉴定:
2.选择终浓度为0mg/ml、8m/ml、16mg/ml、32mg/ml、64mg/ml、128mg/ml的水蛭提取液,分别作用于体外培养的RF/6A 24h后,观察细胞生长情况,以MTT法测定OD值,并计算出24h半数抑制浓度IC_(50),筛选最佳抑制作用的药物浓度;
3.选择终浓度为0u/ml、2.5u/ml、5u/ml、10u/ml、20u/ml的凝血酶,分别作用于体外培养的RF/6A 24h后,观察细胞生长情况,以MTT法测定OD值,筛选最佳诱导增殖的药物浓度:
4.应用流式细胞术,观察水蛭提取液对体外培养的RF/6A细胞周期的影响:
5.应用酶联免疫法,检测各药物组内细胞培养液中MMP-2的含量;
6.应用放射免疫法,检测各药物组内细胞培养液中Ⅳ-C的含量。
结果
1.RF/6A具有血管内皮细胞的特点,Ⅷ因子相关抗原表达阳性,可以用于眼部病变的研究:
2.体外培养的RF/6A指数增长期为48-72h;
3.高浓度水蛭提取液对体外培养的视网膜血管内皮细胞具有抑制增殖作用,低浓度有促进增殖的作用:24hIC_(50)为97mg/ml;选择64mg/ml水蛭提取液为本实验的最佳抑制浓度;
4.20u/ml的凝血酶对体外培养的视网膜血管内皮细胞具有促进增殖作用,选择此浓度用于后期的实验:
5.水蛭提取液将体外培养中视网膜血管内皮细胞的细胞周期抑制于G1期;凝血酶组细胞多处于S期;水蛭提取液抑制了凝血酶对视网膜血管内皮细胞的作用;
6.水蛭提取液可以降低体外培养视网膜血管内皮细胞的ECM中MMP-2的含量,并随时间的增加,其作用有减弱的趋势;凝血酶组随着时间的增加,其作用有增强的趋势;
7.水蛭提取液可以促进体外培养视网膜血管内皮细胞的ECM中Ⅳ-C的合成,并随作用时间的持续,合成有增加趋势;凝血酶组随着作用时间的增加,有轻度促Ⅳ-C的合成增加的趋势,但与正常组相比,有降低Ⅳ-C合成,促进ECM降解作用;2h时水蛭提取液有降低凝血酶促进ECM降解的作用。
结论
1.64mg/ml水蛭提取液对体外培养的视网膜血管内皮细胞具有抑制作用:
2.64mg/ml水蛭提取液可以改变体外培养的凝血酶诱导的视网膜血管内皮细胞的生长周期,对凝血酶诱导的细胞增殖有抑制作用:
3.64mg/ml水蛭提取液促进了体外培养中凝血酶诱导下细胞微环境中Ⅳ-C的合成、抑制了MMP-2的分泌,改变了细胞生长的微环境,对新生血管的形成有抑制作用。
OBJECTIVE
To study the action of leech on retinal vascular epithelium cell in vitro,probe the action and mechanism of leech on anti-Vascularization,and give the prove for exploitation and study on new anti-Vascularization medicine.
METHODS
1.Cultured RF/6A in vitro,and identified cell by immunohistochemical method;
2.Cultured RF/6A in vitro with different final concentration of Extract of leech (0mg/ml、8mg/ml、16mg/ml、32mg/ml、64mg/ml、128mg/ml),used Colorimetry MTT to detect viability of RF/6A at 24 hour,and calculated the 50%inhibitory concentration(IC_(50)) for choosing the right concentration of Exact of leech at 24 hour;
3.Cultured RF/6A in vitro with different final concentration of thrombin(0u/ml、2.5u/ml、5u/ml、10u/ml、20u/ml),and used Colorimetry MTT to detect viability of RF/6A at 24 hour for choosing the right concentration of thrombin;
4.Used flow cytometry to research the influence of Group Extract of leech、Group thrombin、Group mixing and the control on cell cycle of RF/6A cultured in vitro;
5.Used euzymelinked immunosorbent assay to study the influence of every group on MMP-2 of RF/6A cultured in vitro;
6.Used radio-immunity to study the influence of every group onⅣ-C of RF/6A cultured in vitro.
RESULTS
1.RF/6A had the feature of vascular epithelium cells,had positive antigen presentation of factorⅧ,could be usede to study the ophthalmic diseases;
2.Exponential phase of growth of RF/6A cultured in vitro was the 48-72 hour;
3.High concentration of Extract of leech had inhibition on proliferation of retinal vascular endothelial cell cultured in vitro,low concentration had enhancement on proliferation,the 50%inhibitory concentration(IC_(50)) at 24 hour was 97mg/ml,Extract of leech of concentration 64mg/ml was chosen to be the right concentration for this experiment;
4.Thrombin of concentration 20u/ml had enhancement on proliferation of retinal vascular endothelial cell cultured in vitro,and was chosen to be the right concentration for this experiment;
5.Most cells cultured in vitro were in the phrase G1 with Extract of leech,in the Group thrombin most were in the phrase S,Extract of leech had inhibition on the action of thrombin on generation cycle of retinal vascular endothelial cell cultured in vitro;
6.The level of MMP-2 was decreased in Group Extract of leech,and it was increased in Group thrombin in vitro;
7.The synthesis ofⅣ-C was increased in Group Extract of leech in vitro,and it was lightly increased in Group thrombin,while controlled with the normal,it was lower in Group thrombin,thrombin could enhance the degradation of ECM,which could be weekened by leech at 2h.
CONCLUSION
1.Extract of leech of concentration 64mg/ml has the inhibition on proliferation of retinal vascular endothelial cell cultured in vitro;
2.Extract of leech of concentration 64mg/ml can change the growth cycle of retinal vascular endothelial cell cultured in vitro and inhibit the cell proliferation induced by thrombin;
3.Extract of leech of concentration 64mg/ml can increase the synthesis ofⅣ-C, decrease the secretion of MMP-2 in the cell microenvironment cultured in vitro induced by thrombin,and change the microenvironment,maybe Extract of leech has the effect on anti-Vascularization.
引文
1.马晓萍,袁 非.细胞因子与视网膜新生血管的形成[J].中国临床医学.2006,13(5):848-850.
2.刘秀华,田牛.血管生成机制的研究进展[J].中华创伤杂志.2002,18(1):57-59.
3.张平,吴德正.眼部新生血管形成机制及其抑制剂研究进展[J].中国实用眼科杂志.2001,19(10):725-731.
4.中华人民共和国卫生部药典委员会.中华人民共和国药典(一部)[M].第1版.广州:广东科技出版社:1995:67.
5.杨仓良主编.毒药本草[M].第1版.北京:中国中医药出版社.1993年:608.
6.吕文海,王琦.中药水蛭现代研究进展[J].中国中药杂志.1994,19(12):755-759.
7.王筠墨主编.中药研究与临床应用[M].第1版.上海:上海中医药大学出版社.2006:153-154.
8.王文彬,顾袁捷.水蛭对老年冠心病患者血栓素B2和6-酮-前列腺素F1a浓度的影响[J].陕西中医学院学报.2000,23(3):36.
9.肖志坚.水蛭注射液对大白鼠血小板粘附和血小板聚集功能的影响[J].锦州医学院学报.2004,25(5):39.
10.高林,柴立辉,文曙光.水蛭注射液通过降低白细胞浸润减轻鼠脑缺血再灌注损伤[J].河南大学学报.2005,24(3):4-6.
11.董少龙,刁丽梅,窦维华.水蛭注射液对人鼠脑缺血再灌注损伤的防治作用及其机制[J].广西中医药.2004,27(1):47.
12.刘玉华,凌卓荣,张素平,等.复方水蛭合剂对脑缺血再灌注入鼠脑保护机制的研究[J].中国中医急症.2001,10(5):295-296.
13.谢艳华,王四旺,崔翰明.水蛭对正常及血瘀模型大鼠血液流变的影响[J].第四军医人学学报.1996,17(2):52.
14.施利兴,阎政.中药保护血管内皮细胞功能研究进展[J].药物实践杂志.2005,23(6):356-357.
15.张娟,张媛.浅谈水蛭在肿瘤疾病中的应用[J].湖南中医杂志.2006,22(4):69
16.殳迎春,范平国.动物类中药在抗肿瘤方面的应用[J].现代医药卫生.2005,21(20):2821.
17.吕帆,郑燕林,陈海燕,等.水蛭提取液对氨酸蛋白酶介导的牛视网膜色素上皮细胞跨膜信号转导途径的影响[J].中国实用眼科杂志.2007,25(5):549-551.
18.周春阳,郑燕林,盛蓉,等.水蛭提取液对体外培养牛晶状体上皮细胞生长抑制的实验研究[J].中国中医眼科杂志.2006,16(3):157-160.
19.郑燕林,陈海燕,吕帆,等.水蛭提取液对视网膜色素上皮细胞内游离钙离子的影响[J].中国中医眼科杂志.2007,17(1):39-41.
20.王敏,张维东,崔连群,等.水蛭素抑制人脐静脉内皮细胞基质金属蛋白酶-2的生成及活化[J].细胞生物学杂志.2004,4(26):409-412.
21.王敏,崔连群,张承俊,等.水蛭素对凝血酶诱导的血管平滑肌细胞增殖的影响[J].中国动脉硬化杂志.2003,11(7):609-612.
22.郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志.2000,10(1):1-3.
23.郑燕林,王毅,蒋纪恺,等.增生性玻璃体视网膜病变的免疫组化研究及水蛭素的影响[J].眼科.2000,9(2):110-113.
24.郑燕林,蒋纪恺,王万杰,等.水蛭素对外伤性增生性玻璃体视网膜病变细胞外基质的影响[J].中国中医眼科杂志.2001,11(1):5-6.
25.吕帆.2002级成都中医药大学硕士论文[S].
26.孙瑞元,郑青山主编.数学药理学新论[M].第1版.北京:人民卫生出版社.2004年:48-50.
27.刘小雨,王行宽,杨素芳.从肝治心组方对急性心肌梗死大鼠心肌毛细血管密度的影响[J].中国中西医结合急救杂志.2004,11(1):17-19.
28.刘小雨,王行宽.肝与血脉别论[J].中医杂志.2006,46(9):646-647.
29.刘小雨,李国菁,张鹏,等.从肝治心方促血管生成作用及其对缺血性心肌血管内皮生长因子,Ang-1蛋白表达的调节[J].中国临床康复.2006,10(23):76-80.
30.刘小雨,王行宽.促血管新生的中医药治疗现状[J].中国组织工程研究与临床康复.2007,11(10):1918-1922.
31.田残,刘萍,周昱,等.灯盏细辛抑制小鼠视网膜新生血管形成的实验研究[J].医学临床研究.2007,24(3):405-408.
32.李克明,张国,武继彪.水蛭的药理研究概况[J].中医研究.2007,20(2):62-64.
33.曾庆华,王丽英,张玲,等.年龄相关性黄斑变性发生机制与中医辨证分型的关系[J].四川中医.2004,22(2):13-14.
34.黄仲委,关国华,李景恒,等.老年性黄斑变性的中医辨治[J].中医药通报.2002,1(1):14-16.
35.姚大莉.王明芳用内眼辨证治疗老年性黄斑变性[J].四川中..2002,20(6):7-8.
36.接传红,高健生.眼底血证辩证思路探讨[J].山东中医药大学学报.2002,26(4):258-259.
37.周至安,欧扬.唐由之教授治疗老年性黄斑变性的经验[J].广州中医药大学学报.2006,23(3):232-233.
38.周尚昆,崔红培,毛海燕.吕海江教授治疗老年性黄斑变性经验[J].河南中医.2007,27(4):19.
39.梁风鸣,王莉,邓建华.视网膜静脉阻塞的临床难点和中医药治疗体会[J].江苏中医药.2007,39(4):23-24.
40.雷晓琴,贺鹏程,王明芳.视网膜静脉阻塞并发症新生血管的研究现状.国际眼科杂志.2002,2(4):30.
41.陈雪梅,廖志红,张学芬,等.中西医结合防治早期糖尿病视网膜病变的临床效果.现代中西医结合杂志.2007,16(9):1159-1161.
42.王明芳.黄斑部常见的病变表现及其中医认识[J].江苏中医药.2007,39(4):1-2.
43.王华丽.滋阴凉血通络法治疗湿性老年性黄斑变性50例[J].浙江中医杂志.2006,41(10):600.
44.任征,张珠,韩红波.中医治疗高度近视性黄斑出血的临床观察[J].中国中医眼科杂志.2007,17(2):71-72.
45.夏红.运用补虚祛瘀法治疗高度近视性脉络膜视网膜病变的体会.中医研究.2006,19(10):45-46.
46.苏藩,马力,孙丽平,等.复方光明胶囊治疗视网膜静脉阻塞的临床研究[J].云南中医中药杂志.2002,23(2):27.
47.任征,郭平,张环,等.目达明治疗玻璃体积血66例临床观察[J].中国中医药科技.2002,9(4):245-246.
48.高红.中西医结合治疗视网膜静脉周围炎20例[J].河南中医.2007,27(9):62-63.
49.吴德银.活血化瘀为主治疗糖尿病性视网膜病变32例[J].浙江中医杂志.2000,(4):158.
50.张励,唐由之,冯俊.中药治疗湿性老年性黄斑变性临床观察[J].中国中医眼科杂志.2005,15(1):2-4.
51.Ding-An Lou,Funan Hu.Specific antigen and organelle expression of a long-term rhesus endothelial cell line[J].In Vitro Cellular & Developmental Biology -Plant.1987,23(2):75-85.
52.杨红,许为,乌垠,等.牛人然纤溶酶原Kringles结构域片段的获得及其抑制内皮细胞增殖作用研究[J].分子科学学报.2001,17(1):60-63.
53.李光宇,范斌,徐立,等.重组人血管抑制因子Vasostatin对视网膜血管内皮细胞增殖的影响[J].眼科研究.2004,22(4):351-354.
54.Raghava S,Kompella UB.AQ4,an antitumor anthracenedione,inhibits endothelial cell proliferation and vascular endothelial growth factor secretion:Implications for the therapy of ocular neovascular disorders[J].Eur J Pharmacol.2007,568(1-3):68-74.
55.Shen SR,Yu HN,Chen P,et al.Fatty acids in tea shoots(Camellia sinensis(L.) O.Kuntze) and their effects on the growth of retinal RF/6A endothelial cell lines[J].Mol Nutr Food Res.2007,51(2):221-228.
56.胡宝洋,刘坤,万瑾,等.阻断神经生长因子信号部分抑制雌二醇对恒河猴视网膜血管内皮细胞的作用[J].解剖学报.2004,35(6):612-616.
57.于文贞,黎晓新,周国宏,等.P13K抑制剂对体外培养的眼底血管内皮细胞的作用[J].眼科研究.2007,25(2):117-120,
58.许建华,刘哲丽,李若溪,等.曲安奈德对缺氧条件下恒河猴脉络膜视网膜内皮细胞VEGF表达的影响[J].国际眼科杂志.2006,6(5):1053-1055.
59.薛庆善.体外培养原理与技术[M].第1版,北京:科学出版社.2001:51-482.
60.Yang Z.Ruschitzka F,Rabelink TJ,et al.Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vesels,Implications for venous bypass graft failure[J].Circulation.1997,95:1870-1876.
61.石建霞,顾 健.凝血酶与肿瘤的血管新生[J].中国实验血液学杂志.2006,14(1):197-200.
62.王敏,王晓军,崔连群.凝血酶与血管内皮细胞[J].细胞生物学杂志.2005,27:57-60.
63.辛华,郑雅娟,韩振国,等.凝血酶影响血管内皮细胞通透性的实验研究[J].吉林大学学报(医学版).2003,29(5):640-643.
64.Tsopanoglou NE,Maragoudakis ME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost.2004,30(1):63-69.
65.Maragoudakis ME,Tsopanoglou NE,Andriopoulou P.Mechanism of thrombin-induced angiogenesis[J].Biochern Soc Trans.2002,30(2):173-177.
66.Tsopanoglou NE,Maragoudakis ME.On the mechanism of thrombin-induced angiogenesis.Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors[J].J Biol Chem.1999;274(34):23969-23976.
67.Nobe K,Sone T,Paul RJ,et al.Thrombin-Induced Force Development in Vascular Endothelial Cells:Contribution to Alteration of Permeability Mediated by Calcium -Dependent and -Independent Pathways[J].JPharraacol Sci.2005,99(3):252-263.
68.辛华,郑雅娟,韩振国,等.凝血酶影响血管内皮细胞通透性的实验研究[J].吉林大学学报(医学版).2003,29(5):640-642.
69.王敏,崔连群,王晓军,等.水蛭素对凝血酶诱导血管内皮细胞与中性粒细胞表达黏粘附分子的影响[J].中国新药杂志.2005,14(8):989-892.
70.高春林,范生尧,贾俊,等.凝血酶致脑微血管内皮细胞凋亡作用[J].中华老年多器官疾病杂志.2005,4(1):57.
71.何庆南,易著文,陈香美,等.凝血酶诱导人胚胎肾系膜细胞增殖和PAI-1表达的研究[J].湖南医科大学学报.2000,25(2):191-201.
72.郑练,方驰华.灯盏花对人脐静脉内皮细胞组织因子转录及表达的影响.南方医科大学学报.2007,27(6):806.
73.朱应葆,钱鑫,贾廷珍.肿瘤治疗的新靶点--细胞周期检定点[J].中华放射医学与防护杂志.2006.26(1):1-2.
74.Das A,McLamore A,Song W,et al.Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor[J].Arch Ophthalmol.1999,117(4):498-503.
75.Adithi M,Nalini V,Kandalam M.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].JPediatr Hematol Oncol.2007,29(6):399-405.
76.Burbridge MF,Cogé F,Galizzi JP,et al.The role of the matrix metalloproteinases during in vitro vessel formation[J].Angiogenesis.2002,5(3):215-226.
77.Hrabec E,Naduk J,Strek M,et al.Type Ⅳ collagenases(MMP-2 and MMP-9) and their substrates-intracellular proteins,hormones,cytokines,chemokines and their receptors[J].Postepy Biochem.2007,53(1):37-45.
78.Shima I,Katsuda S,Ueda Y,et al.Expression of Matrix Metalloproteinases in Wound Healing after Glaucoma Filtration Surgery in Rabbits[J].Ophthalmic Res.2007,22;39(6):315-324.
79.Fu X,Parks WC,Heinecke JW.Activation and silencing of matrix metalloproteinases[J].Semin Cell Dev Biol.2008;19(1):2-13.
80.车绪春,陆融,姚智.基质金属蛋白酶在肿瘤血管生成中的作用[J].国际肿瘤学杂志.2007,34(2):84-87.
81.Barnett JM,McCollum GW,Fowler JA,et al.Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR[J].Invest Ophthalmol Vis Sci.2007,48(2):907-915.
82.Sánchez MC,Barcelona PF,Luna JD,et al.Low-density lipoprotein receptor-related protein-1(LRP-1) expression in a rat model of oxygen-induced retinal neovascularization[J].Exp Eye Res.2006;83(6):1378-1385.
83.Kvanta A,Shen WY,Sarman S,et al.Matrix metalloproteinase(MMP) expression in experimental choroidal neovascularization[J].Curr Eye Res.2000,2 l(3):684-690.
84.He T,Xing YQ,Zhao XH,et al.Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice[J].Arch Med Res.2007;38(8):807-815.
85.Navaratna D,McGuire PG,Menicucci G,et al.Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes[J].Diabetes.2007;56(9):2380-2387.
86.Hoffmann S,He S,Ehren M,et al.MMP-2andMMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes[J].Retina.2006;26(4):454-461.
87.Giebel SJ,Menicucci G,McGuire PG,et al.Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier[J].Lab Invest.2005;85(5):597-607.
88.Adithi M,Nalini V,Kandalam M,et al.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].J Pediatr Hematol Oncol.2007;29(6):399-405.
89.Yamada E,Yobe T,Yamada H,et al.TIMP-1 promotes VEGF-induced neovascularization in the retina[J].Histol Histopathol.2001;16(1):87-97.
90.李玉英,钱桂生,黄桂君.血管生成抑制剂Canstatin研究概况[J].生物医学工程学杂志.2005,22(3):626-628.
91.Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression[J].Nat Rev Cancer.2002,2(3):161-174.
92.Jeong JW,Cha HJ,Yu DY,et al.Induction of membrane-type matrix metalloproteinase-1stimulates angiogenic activities of bovine aortic endothelial cells[J].Angiogenesis.1999,3(2):167-174.
93.陈陆霞,张诗武,孙保存,等.MMP-2,MMP-9的表达与脉络膜黑色素瘤微血管密度及肿瘤转移的关系[J].眼科新进展.2007,27(8):565-567.
1.曾平.中药为主治疗视网膜静脉周围炎[J].湖北中医杂志.2002,24(2):34-35.
2.王明芳,梁凤鸣,雷晓琴.王明芳教授分期论治眼底出血症的经验[J].成都中医药大学学报.1999,22(1):1-2.
3.接传红,高健生.眼底血证辨证论治思路探讨[J].山东中医药大学学报.2002,26(4):258-259.
4.郗惠毅.中药分期治疗视网膜静脉周围炎25例[J].中国中医急症.2003,12(3):279.
5.赵君青,杨光.中药为主治疗视网膜静脉周围炎临床观察[J].天津中医.2001,18(3):19-20.
6.钱爱华.沈汝才治疗眼底血证经验[J].湖北中医杂志.1999,21(4):156.
7.刘鑫,晋昱晟.中西医结合治疗视网膜静脉周围炎[J].山西职工医院学报.2002,12(1):32-33.
8.张愈延.中西医结合治疗视网膜静脉周围炎31例[J].江西中医药.2002,33(6):32.
9.孔德兰,刘秀玉,杨华,等.中西医结合治疗视网膜静脉周围炎55例[J].河北中医.1999,21(6):376-377.
10.陈春光,赵明,豆丽,等.中西医结合治疗视网膜静脉周围炎21例[J].实用中医药杂志.1999,15(7):26.
11.王卫红.中西医结合治疗视网膜静脉周围炎20例[J].首都医药.1999,6(2):43.
12.李淑琳.中西医结合治疗视网膜静脉周围炎观察[J].实用中医药杂志.1999,15(7):22-23.
13.徐红.中西医结合治疗视网膜静脉周围炎[J].眼科新进展.2002,22(2):132.
14.赵宏范.中医药为主治疗视网膜静脉周围炎32例[J].河南中医药学刊.1999,14(6):38-39.
15.曾明葵,李建超.加味四妙勇安汤治疗视网膜静脉周围炎临床观察[J].湖南中医学院学报.2004,24(4):44-45.
1.GraggAH,EimzigS,RyssoyJA,et al.The vasa dasoprum and angioplasty[J].Radiology.1983,48:75-80.
2.Zhang YX.Chif WJ,Sehoefl GI.Immunohistochemical study of intinal macroveasels incoronary atheroselerosis[J].Radiology.1983,148:75-80.
3.Das A,McLamore A,Song W,et al.Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor[J].Arch Ophthalmol.1999,117(4):498-503.
4.Burbridge MF,Cogé F,Galizzi JP,et al.The role of the matrix metalloproteinases during in vitro vessel formation[J].Angiogenesis.2002,5(3):215-226.
5.Duffy MJ,McGowan PM,Gallagher WM.Cancer invasion and metastasis:changing views[J].J Pathol.2008;214(3):283-29 3.
6.车绪春,陆融,姚智.基质金属蛋白酶在肿瘤血管生成中的作用[J].国际肿瘤学杂志.2007,34(2):84-87.
7.Hrabec E,Naduk J,Strek M,et al.Type Ⅳ collagenases(MMP-2 and MMP-9) and their substrates-intracellular proteins,hormones,cytokines,chemokines and their receptors[J].Postepy Biochem.2007,53(1):37-45.
8.Shima I,Katsuda S,Ueda Y,et al.Expression of Matrix Metalloproteinases in Wound Healing after Glaucoma Filtration Surgery in Rabbits[J].Ophthahnic Res.2007,22;39(6):315-324.
9.Fu X,Parks WC,Heinecke JW.Activation and silencing of matrix metalloproteinases[J].Semin Cell Dev Biol.2008;19(1):2-13.
10.Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression[J].Nature Rev.Cancer.2002,2(3):161 - 174.
11.Francesca Spinella,Laura Rosanò,Valeriana Di Castro,et al.Endothelin-1 and Endothelin-3Promote Invasive Behavior via Hypoxia-Inducible Factor-1(?) in Human Melanoma Cells[J].Cancer Res.2007;67(4):1725-1734.
12.Currie JC,Fortier S,Sina A,et al.MTI-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells:a molecular link between pro-MMP-2activation,chemotaxis,and cell survival[J].J Biol Chem.2007;282(11):8142-8149.
13.Schmidt R,Bültmann A,Ungerer M,et al.Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells:implications in acute myocardial infarction[J].Circulation.2006;113(6):834-841.
14.张雷,张士胜,石海云,等.经瞳孔温热疗法照射对视网膜组织中VEGF和MMP-1m RNA表达的影响[J].眼科新进展.2007,27(6):413-416.
15.曾 军,姜德咏,刘湘平,等.MMP-2和MMP-9在脉络膜新生血管膜的表达[J].眼科新进展.2004,24(6):455-457.
16.张士胜,王康孙,王玲,等.MMP-9及TIMP-3在小鼠脉络膜新生血管形成中的作用[J].上海第二医科大学学报,2003,23(3):206-209.
17.陈陆霞,张诗武,孙保存,等.MMP-2,MMP-9的表达与脉络膜黑色素瘤微血管密度及肿瘤转移的关系[J].眼科新进展.2007,27(8):565-567.
18.Flaxel C,Bradle J,Acott T,et al.Retinal pigment epithelium produces matrix metalloproteinases after laser treatment[J].Retina.2007;27(5):629-634.
19.He T,Xing YQ,Zhao XH,et al.Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice[J].Arch Med Res.2007;38(8):807-815.
20.Yang R,Liu H,Williams I,et al.Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes:implications in diabetic retinopathy[J].Ann N Y Acad Sci.2007;1103:196-201.
21.Navaratna D,McGuire PG.Menicucci G.et al.Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes[J].Diabetes.2007;56(9):2380-2387.
22.Hoffmann S,He S,Ehren M,et al.MMP-2andMMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes[J].Retina.2006;26(4):454-461.
23.Sánchez MC,Barcelona PF,Luna JD,et al.Low-density lipoprotein receptor-related protein-1(LRP-1) expression in a rat model of oxygen-induced retinal neovascularization[J].Exp Eye Res.2006;83(6):1378-1385.
24.Descamps FJ,Martens E,Kangave D,et al.The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage[J].Exp Eye Res.2006;83(2):401-407.
25.Giebel SJ,Menicucci G,McGuire PG,et al.Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier[J].Lab lnvest.2005;85(5):597-607.
26.Adithi M,Nalini V,Kandalam M,et al.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].J Pediatr Heraatol Oncol.2007;29(6):399-405.
27.Jin M,Kashiwagi K,Iizuka Y,et al.Matrix metalloproteinases in human diabetic and nondiabetic vitreous[J].Retina.2001;21(1):28-33.
28.Majka S,McGuire PG,Das A.Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization[J].Invest Ophthalmol Vis Sci.2002;43(1):260-266.
29.Yamada E,Yobe T,Yamada H,et al.TIMP-1 promotes VEGF-induced neovascularization in the retina[J].Histol Histopathol.2001;16(1):87-97.
2.刘秀华,田牛.血管生成机制的研究进展[J].中华创伤杂志.2002,18(1):57-59.
3.张平,吴德正.眼部新生血管形成机制及其抑制剂研究进展[J].中国实用眼科杂志.2001,19(10):725-731.
4.中华人民共和国卫生部药典委员会.中华人民共和国药典(一部)[M].第1版.广州:广东科技出版社:1995:67.
5.杨仓良主编.毒药本草[M].第1版.北京:中国中医药出版社.1993年:608.
6.吕文海,王琦.中药水蛭现代研究进展[J].中国中药杂志.1994,19(12):755-759.
7.王筠墨主编.中药研究与临床应用[M].第1版.上海:上海中医药大学出版社.2006:153-154.
8.王文彬,顾袁捷.水蛭对老年冠心病患者血栓素B2和6-酮-前列腺素F1a浓度的影响[J].陕西中医学院学报.2000,23(3):36.
9.肖志坚.水蛭注射液对大白鼠血小板粘附和血小板聚集功能的影响[J].锦州医学院学报.2004,25(5):39.
10.高林,柴立辉,文曙光.水蛭注射液通过降低白细胞浸润减轻鼠脑缺血再灌注损伤[J].河南大学学报.2005,24(3):4-6.
11.董少龙,刁丽梅,窦维华.水蛭注射液对人鼠脑缺血再灌注损伤的防治作用及其机制[J].广西中医药.2004,27(1):47.
12.刘玉华,凌卓荣,张素平,等.复方水蛭合剂对脑缺血再灌注入鼠脑保护机制的研究[J].中国中医急症.2001,10(5):295-296.
13.谢艳华,王四旺,崔翰明.水蛭对正常及血瘀模型大鼠血液流变的影响[J].第四军医人学学报.1996,17(2):52.
14.施利兴,阎政.中药保护血管内皮细胞功能研究进展[J].药物实践杂志.2005,23(6):356-357.
15.张娟,张媛.浅谈水蛭在肿瘤疾病中的应用[J].湖南中医杂志.2006,22(4):69
16.殳迎春,范平国.动物类中药在抗肿瘤方面的应用[J].现代医药卫生.2005,21(20):2821.
17.吕帆,郑燕林,陈海燕,等.水蛭提取液对氨酸蛋白酶介导的牛视网膜色素上皮细胞跨膜信号转导途径的影响[J].中国实用眼科杂志.2007,25(5):549-551.
18.周春阳,郑燕林,盛蓉,等.水蛭提取液对体外培养牛晶状体上皮细胞生长抑制的实验研究[J].中国中医眼科杂志.2006,16(3):157-160.
19.郑燕林,陈海燕,吕帆,等.水蛭提取液对视网膜色素上皮细胞内游离钙离子的影响[J].中国中医眼科杂志.2007,17(1):39-41.
20.王敏,张维东,崔连群,等.水蛭素抑制人脐静脉内皮细胞基质金属蛋白酶-2的生成及活化[J].细胞生物学杂志.2004,4(26):409-412.
21.王敏,崔连群,张承俊,等.水蛭素对凝血酶诱导的血管平滑肌细胞增殖的影响[J].中国动脉硬化杂志.2003,11(7):609-612.
22.郑燕林,王毅,袁晓辉,等.水蛭素对增生性玻璃体视网膜病变影响的组织病理学观察[J].中国中医眼科杂志.2000,10(1):1-3.
23.郑燕林,王毅,蒋纪恺,等.增生性玻璃体视网膜病变的免疫组化研究及水蛭素的影响[J].眼科.2000,9(2):110-113.
24.郑燕林,蒋纪恺,王万杰,等.水蛭素对外伤性增生性玻璃体视网膜病变细胞外基质的影响[J].中国中医眼科杂志.2001,11(1):5-6.
25.吕帆.2002级成都中医药大学硕士论文[S].
26.孙瑞元,郑青山主编.数学药理学新论[M].第1版.北京:人民卫生出版社.2004年:48-50.
27.刘小雨,王行宽,杨素芳.从肝治心组方对急性心肌梗死大鼠心肌毛细血管密度的影响[J].中国中西医结合急救杂志.2004,11(1):17-19.
28.刘小雨,王行宽.肝与血脉别论[J].中医杂志.2006,46(9):646-647.
29.刘小雨,李国菁,张鹏,等.从肝治心方促血管生成作用及其对缺血性心肌血管内皮生长因子,Ang-1蛋白表达的调节[J].中国临床康复.2006,10(23):76-80.
30.刘小雨,王行宽.促血管新生的中医药治疗现状[J].中国组织工程研究与临床康复.2007,11(10):1918-1922.
31.田残,刘萍,周昱,等.灯盏细辛抑制小鼠视网膜新生血管形成的实验研究[J].医学临床研究.2007,24(3):405-408.
32.李克明,张国,武继彪.水蛭的药理研究概况[J].中医研究.2007,20(2):62-64.
33.曾庆华,王丽英,张玲,等.年龄相关性黄斑变性发生机制与中医辨证分型的关系[J].四川中医.2004,22(2):13-14.
34.黄仲委,关国华,李景恒,等.老年性黄斑变性的中医辨治[J].中医药通报.2002,1(1):14-16.
35.姚大莉.王明芳用内眼辨证治疗老年性黄斑变性[J].四川中..2002,20(6):7-8.
36.接传红,高健生.眼底血证辩证思路探讨[J].山东中医药大学学报.2002,26(4):258-259.
37.周至安,欧扬.唐由之教授治疗老年性黄斑变性的经验[J].广州中医药大学学报.2006,23(3):232-233.
38.周尚昆,崔红培,毛海燕.吕海江教授治疗老年性黄斑变性经验[J].河南中医.2007,27(4):19.
39.梁风鸣,王莉,邓建华.视网膜静脉阻塞的临床难点和中医药治疗体会[J].江苏中医药.2007,39(4):23-24.
40.雷晓琴,贺鹏程,王明芳.视网膜静脉阻塞并发症新生血管的研究现状.国际眼科杂志.2002,2(4):30.
41.陈雪梅,廖志红,张学芬,等.中西医结合防治早期糖尿病视网膜病变的临床效果.现代中西医结合杂志.2007,16(9):1159-1161.
42.王明芳.黄斑部常见的病变表现及其中医认识[J].江苏中医药.2007,39(4):1-2.
43.王华丽.滋阴凉血通络法治疗湿性老年性黄斑变性50例[J].浙江中医杂志.2006,41(10):600.
44.任征,张珠,韩红波.中医治疗高度近视性黄斑出血的临床观察[J].中国中医眼科杂志.2007,17(2):71-72.
45.夏红.运用补虚祛瘀法治疗高度近视性脉络膜视网膜病变的体会.中医研究.2006,19(10):45-46.
46.苏藩,马力,孙丽平,等.复方光明胶囊治疗视网膜静脉阻塞的临床研究[J].云南中医中药杂志.2002,23(2):27.
47.任征,郭平,张环,等.目达明治疗玻璃体积血66例临床观察[J].中国中医药科技.2002,9(4):245-246.
48.高红.中西医结合治疗视网膜静脉周围炎20例[J].河南中医.2007,27(9):62-63.
49.吴德银.活血化瘀为主治疗糖尿病性视网膜病变32例[J].浙江中医杂志.2000,(4):158.
50.张励,唐由之,冯俊.中药治疗湿性老年性黄斑变性临床观察[J].中国中医眼科杂志.2005,15(1):2-4.
51.Ding-An Lou,Funan Hu.Specific antigen and organelle expression of a long-term rhesus endothelial cell line[J].In Vitro Cellular & Developmental Biology -Plant.1987,23(2):75-85.
52.杨红,许为,乌垠,等.牛人然纤溶酶原Kringles结构域片段的获得及其抑制内皮细胞增殖作用研究[J].分子科学学报.2001,17(1):60-63.
53.李光宇,范斌,徐立,等.重组人血管抑制因子Vasostatin对视网膜血管内皮细胞增殖的影响[J].眼科研究.2004,22(4):351-354.
54.Raghava S,Kompella UB.AQ4,an antitumor anthracenedione,inhibits endothelial cell proliferation and vascular endothelial growth factor secretion:Implications for the therapy of ocular neovascular disorders[J].Eur J Pharmacol.2007,568(1-3):68-74.
55.Shen SR,Yu HN,Chen P,et al.Fatty acids in tea shoots(Camellia sinensis(L.) O.Kuntze) and their effects on the growth of retinal RF/6A endothelial cell lines[J].Mol Nutr Food Res.2007,51(2):221-228.
56.胡宝洋,刘坤,万瑾,等.阻断神经生长因子信号部分抑制雌二醇对恒河猴视网膜血管内皮细胞的作用[J].解剖学报.2004,35(6):612-616.
57.于文贞,黎晓新,周国宏,等.P13K抑制剂对体外培养的眼底血管内皮细胞的作用[J].眼科研究.2007,25(2):117-120,
58.许建华,刘哲丽,李若溪,等.曲安奈德对缺氧条件下恒河猴脉络膜视网膜内皮细胞VEGF表达的影响[J].国际眼科杂志.2006,6(5):1053-1055.
59.薛庆善.体外培养原理与技术[M].第1版,北京:科学出版社.2001:51-482.
60.Yang Z.Ruschitzka F,Rabelink TJ,et al.Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vesels,Implications for venous bypass graft failure[J].Circulation.1997,95:1870-1876.
61.石建霞,顾 健.凝血酶与肿瘤的血管新生[J].中国实验血液学杂志.2006,14(1):197-200.
62.王敏,王晓军,崔连群.凝血酶与血管内皮细胞[J].细胞生物学杂志.2005,27:57-60.
63.辛华,郑雅娟,韩振国,等.凝血酶影响血管内皮细胞通透性的实验研究[J].吉林大学学报(医学版).2003,29(5):640-643.
64.Tsopanoglou NE,Maragoudakis ME.Role of thrombin in angiogenesis and tumor progression[J].Semin Thromb Hemost.2004,30(1):63-69.
65.Maragoudakis ME,Tsopanoglou NE,Andriopoulou P.Mechanism of thrombin-induced angiogenesis[J].Biochern Soc Trans.2002,30(2):173-177.
66.Tsopanoglou NE,Maragoudakis ME.On the mechanism of thrombin-induced angiogenesis.Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors[J].J Biol Chem.1999;274(34):23969-23976.
67.Nobe K,Sone T,Paul RJ,et al.Thrombin-Induced Force Development in Vascular Endothelial Cells:Contribution to Alteration of Permeability Mediated by Calcium -Dependent and -Independent Pathways[J].JPharraacol Sci.2005,99(3):252-263.
68.辛华,郑雅娟,韩振国,等.凝血酶影响血管内皮细胞通透性的实验研究[J].吉林大学学报(医学版).2003,29(5):640-642.
69.王敏,崔连群,王晓军,等.水蛭素对凝血酶诱导血管内皮细胞与中性粒细胞表达黏粘附分子的影响[J].中国新药杂志.2005,14(8):989-892.
70.高春林,范生尧,贾俊,等.凝血酶致脑微血管内皮细胞凋亡作用[J].中华老年多器官疾病杂志.2005,4(1):57.
71.何庆南,易著文,陈香美,等.凝血酶诱导人胚胎肾系膜细胞增殖和PAI-1表达的研究[J].湖南医科大学学报.2000,25(2):191-201.
72.郑练,方驰华.灯盏花对人脐静脉内皮细胞组织因子转录及表达的影响.南方医科大学学报.2007,27(6):806.
73.朱应葆,钱鑫,贾廷珍.肿瘤治疗的新靶点--细胞周期检定点[J].中华放射医学与防护杂志.2006.26(1):1-2.
74.Das A,McLamore A,Song W,et al.Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor[J].Arch Ophthalmol.1999,117(4):498-503.
75.Adithi M,Nalini V,Kandalam M.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].JPediatr Hematol Oncol.2007,29(6):399-405.
76.Burbridge MF,Cogé F,Galizzi JP,et al.The role of the matrix metalloproteinases during in vitro vessel formation[J].Angiogenesis.2002,5(3):215-226.
77.Hrabec E,Naduk J,Strek M,et al.Type Ⅳ collagenases(MMP-2 and MMP-9) and their substrates-intracellular proteins,hormones,cytokines,chemokines and their receptors[J].Postepy Biochem.2007,53(1):37-45.
78.Shima I,Katsuda S,Ueda Y,et al.Expression of Matrix Metalloproteinases in Wound Healing after Glaucoma Filtration Surgery in Rabbits[J].Ophthalmic Res.2007,22;39(6):315-324.
79.Fu X,Parks WC,Heinecke JW.Activation and silencing of matrix metalloproteinases[J].Semin Cell Dev Biol.2008;19(1):2-13.
80.车绪春,陆融,姚智.基质金属蛋白酶在肿瘤血管生成中的作用[J].国际肿瘤学杂志.2007,34(2):84-87.
81.Barnett JM,McCollum GW,Fowler JA,et al.Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR[J].Invest Ophthalmol Vis Sci.2007,48(2):907-915.
82.Sánchez MC,Barcelona PF,Luna JD,et al.Low-density lipoprotein receptor-related protein-1(LRP-1) expression in a rat model of oxygen-induced retinal neovascularization[J].Exp Eye Res.2006;83(6):1378-1385.
83.Kvanta A,Shen WY,Sarman S,et al.Matrix metalloproteinase(MMP) expression in experimental choroidal neovascularization[J].Curr Eye Res.2000,2 l(3):684-690.
84.He T,Xing YQ,Zhao XH,et al.Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice[J].Arch Med Res.2007;38(8):807-815.
85.Navaratna D,McGuire PG,Menicucci G,et al.Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes[J].Diabetes.2007;56(9):2380-2387.
86.Hoffmann S,He S,Ehren M,et al.MMP-2andMMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes[J].Retina.2006;26(4):454-461.
87.Giebel SJ,Menicucci G,McGuire PG,et al.Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier[J].Lab Invest.2005;85(5):597-607.
88.Adithi M,Nalini V,Kandalam M,et al.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].J Pediatr Hematol Oncol.2007;29(6):399-405.
89.Yamada E,Yobe T,Yamada H,et al.TIMP-1 promotes VEGF-induced neovascularization in the retina[J].Histol Histopathol.2001;16(1):87-97.
90.李玉英,钱桂生,黄桂君.血管生成抑制剂Canstatin研究概况[J].生物医学工程学杂志.2005,22(3):626-628.
91.Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression[J].Nat Rev Cancer.2002,2(3):161-174.
92.Jeong JW,Cha HJ,Yu DY,et al.Induction of membrane-type matrix metalloproteinase-1stimulates angiogenic activities of bovine aortic endothelial cells[J].Angiogenesis.1999,3(2):167-174.
93.陈陆霞,张诗武,孙保存,等.MMP-2,MMP-9的表达与脉络膜黑色素瘤微血管密度及肿瘤转移的关系[J].眼科新进展.2007,27(8):565-567.
1.曾平.中药为主治疗视网膜静脉周围炎[J].湖北中医杂志.2002,24(2):34-35.
2.王明芳,梁凤鸣,雷晓琴.王明芳教授分期论治眼底出血症的经验[J].成都中医药大学学报.1999,22(1):1-2.
3.接传红,高健生.眼底血证辨证论治思路探讨[J].山东中医药大学学报.2002,26(4):258-259.
4.郗惠毅.中药分期治疗视网膜静脉周围炎25例[J].中国中医急症.2003,12(3):279.
5.赵君青,杨光.中药为主治疗视网膜静脉周围炎临床观察[J].天津中医.2001,18(3):19-20.
6.钱爱华.沈汝才治疗眼底血证经验[J].湖北中医杂志.1999,21(4):156.
7.刘鑫,晋昱晟.中西医结合治疗视网膜静脉周围炎[J].山西职工医院学报.2002,12(1):32-33.
8.张愈延.中西医结合治疗视网膜静脉周围炎31例[J].江西中医药.2002,33(6):32.
9.孔德兰,刘秀玉,杨华,等.中西医结合治疗视网膜静脉周围炎55例[J].河北中医.1999,21(6):376-377.
10.陈春光,赵明,豆丽,等.中西医结合治疗视网膜静脉周围炎21例[J].实用中医药杂志.1999,15(7):26.
11.王卫红.中西医结合治疗视网膜静脉周围炎20例[J].首都医药.1999,6(2):43.
12.李淑琳.中西医结合治疗视网膜静脉周围炎观察[J].实用中医药杂志.1999,15(7):22-23.
13.徐红.中西医结合治疗视网膜静脉周围炎[J].眼科新进展.2002,22(2):132.
14.赵宏范.中医药为主治疗视网膜静脉周围炎32例[J].河南中医药学刊.1999,14(6):38-39.
15.曾明葵,李建超.加味四妙勇安汤治疗视网膜静脉周围炎临床观察[J].湖南中医学院学报.2004,24(4):44-45.
1.GraggAH,EimzigS,RyssoyJA,et al.The vasa dasoprum and angioplasty[J].Radiology.1983,48:75-80.
2.Zhang YX.Chif WJ,Sehoefl GI.Immunohistochemical study of intinal macroveasels incoronary atheroselerosis[J].Radiology.1983,148:75-80.
3.Das A,McLamore A,Song W,et al.Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor[J].Arch Ophthalmol.1999,117(4):498-503.
4.Burbridge MF,Cogé F,Galizzi JP,et al.The role of the matrix metalloproteinases during in vitro vessel formation[J].Angiogenesis.2002,5(3):215-226.
5.Duffy MJ,McGowan PM,Gallagher WM.Cancer invasion and metastasis:changing views[J].J Pathol.2008;214(3):283-29 3.
6.车绪春,陆融,姚智.基质金属蛋白酶在肿瘤血管生成中的作用[J].国际肿瘤学杂志.2007,34(2):84-87.
7.Hrabec E,Naduk J,Strek M,et al.Type Ⅳ collagenases(MMP-2 and MMP-9) and their substrates-intracellular proteins,hormones,cytokines,chemokines and their receptors[J].Postepy Biochem.2007,53(1):37-45.
8.Shima I,Katsuda S,Ueda Y,et al.Expression of Matrix Metalloproteinases in Wound Healing after Glaucoma Filtration Surgery in Rabbits[J].Ophthahnic Res.2007,22;39(6):315-324.
9.Fu X,Parks WC,Heinecke JW.Activation and silencing of matrix metalloproteinases[J].Semin Cell Dev Biol.2008;19(1):2-13.
10.Egeblad M,Werb Z.New functions for the matrix metalloproteinases in cancer progression[J].Nature Rev.Cancer.2002,2(3):161 - 174.
11.Francesca Spinella,Laura Rosanò,Valeriana Di Castro,et al.Endothelin-1 and Endothelin-3Promote Invasive Behavior via Hypoxia-Inducible Factor-1(?) in Human Melanoma Cells[J].Cancer Res.2007;67(4):1725-1734.
12.Currie JC,Fortier S,Sina A,et al.MTI-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells:a molecular link between pro-MMP-2activation,chemotaxis,and cell survival[J].J Biol Chem.2007;282(11):8142-8149.
13.Schmidt R,Bültmann A,Ungerer M,et al.Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells:implications in acute myocardial infarction[J].Circulation.2006;113(6):834-841.
14.张雷,张士胜,石海云,等.经瞳孔温热疗法照射对视网膜组织中VEGF和MMP-1m RNA表达的影响[J].眼科新进展.2007,27(6):413-416.
15.曾 军,姜德咏,刘湘平,等.MMP-2和MMP-9在脉络膜新生血管膜的表达[J].眼科新进展.2004,24(6):455-457.
16.张士胜,王康孙,王玲,等.MMP-9及TIMP-3在小鼠脉络膜新生血管形成中的作用[J].上海第二医科大学学报,2003,23(3):206-209.
17.陈陆霞,张诗武,孙保存,等.MMP-2,MMP-9的表达与脉络膜黑色素瘤微血管密度及肿瘤转移的关系[J].眼科新进展.2007,27(8):565-567.
18.Flaxel C,Bradle J,Acott T,et al.Retinal pigment epithelium produces matrix metalloproteinases after laser treatment[J].Retina.2007;27(5):629-634.
19.He T,Xing YQ,Zhao XH,et al.Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice[J].Arch Med Res.2007;38(8):807-815.
20.Yang R,Liu H,Williams I,et al.Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes:implications in diabetic retinopathy[J].Ann N Y Acad Sci.2007;1103:196-201.
21.Navaratna D,McGuire PG.Menicucci G.et al.Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes[J].Diabetes.2007;56(9):2380-2387.
22.Hoffmann S,He S,Ehren M,et al.MMP-2andMMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes[J].Retina.2006;26(4):454-461.
23.Sánchez MC,Barcelona PF,Luna JD,et al.Low-density lipoprotein receptor-related protein-1(LRP-1) expression in a rat model of oxygen-induced retinal neovascularization[J].Exp Eye Res.2006;83(6):1378-1385.
24.Descamps FJ,Martens E,Kangave D,et al.The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage[J].Exp Eye Res.2006;83(2):401-407.
25.Giebel SJ,Menicucci G,McGuire PG,et al.Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier[J].Lab lnvest.2005;85(5):597-607.
26.Adithi M,Nalini V,Kandalam M,et al.Expression of matrix metalloproteinases and their inhibitors in retinoblastoma[J].J Pediatr Heraatol Oncol.2007;29(6):399-405.
27.Jin M,Kashiwagi K,Iizuka Y,et al.Matrix metalloproteinases in human diabetic and nondiabetic vitreous[J].Retina.2001;21(1):28-33.
28.Majka S,McGuire PG,Das A.Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization[J].Invest Ophthalmol Vis Sci.2002;43(1):260-266.
29.Yamada E,Yobe T,Yamada H,et al.TIMP-1 promotes VEGF-induced neovascularization in the retina[J].Histol Histopathol.2001;16(1):87-97.